Traduction de «well-being and to demonstrate » (Néerlandais → Français) :

TERMINOLOGIE

eosinofiele cellulitis [Wells]
Phlegmon à éosinophiles [Wells]

gevreesde aandoening niet aangetoond | probleem is normale situatie | worried well
Affection non prouvée Bien-portant inquiet

TRADUCTIONS EN CONTEXTE

It is a person’s ability to maintain a state of mental well-being and to demonstrate this in adaptive and positive behavior while interacting with others, his/her culture environment.
C’est l’aptitude d’une personne à maintenir un état de bien-être mental, en adaptant un comportement approprié et positif, à l’occasion des relations entretenues avec les autres, sa propre culture et son environnement.

Training module The following GP organisations have co-operated in view of providing support to general practitioners, as well as improving their competence: the “Vlaams Huisartsen Navormingsinstituut” (VHNI), the “Interuniversitair Centrum voor Huisartsenvorming” (ICHO) and the “Wetenschappelijke Verenining voor Vlaamse Huisartsen” (WVVH) (recently integrated in Domus Medica), as well as the “LOGO” doctors.
Module de formation Dans le cadre du soutien et du développement des compétences des médecins généralistes les organisations de médecins généralistes suivantes ont collaboré: le Vlaams Huisartsen Navormingsinstituut (VHNI), l’Interuniversitair Centrum voor Huisartsenvorming (ICHO) et la Wetenschappelijke Vereniging voor Vlaamse Huisartsen (WVVH), récemment intégrées dans Domus Medica, ainsi qu’avec les médecins « LOGO ».

About Humana Humana Inc., headquartered in Louisville, Kentucky, is a leading healthcare company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being.
Humana Inc., headquartered in Louisville, Kentucky, is a leading healthcare company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being.

Unfortunately, the scientific studies that demonstrate the suicide prevention effect of altering specific risk or protective factors remain limited in number.
Malheureusement, les études scientifiques qui démontrent que modifier des facteurs de risque ou de protection spécifiques a un effet sur la prévention du suicide, sont toujours très peu nombreuses.

More recent versions have demonstrated adequate performance (sensitivity > 97%), including the Vitek II system (bioMérieux) and Micro Scan Rapid (Dade Behring).
Des versions plus récentes ont fait preuve de performances adéquates (sensibilité > 97%), en ce compris le système Vitek II (bioMérieux) et Micro Scan Rapid (Dade Behring).

The golden standard for confirming oxacillin-resistance is demonstrating the presence of the mecA gene by means of PCR.
Le critère de référence pour confirmer la résistance à l’oxacilline consiste à mettre en évidence le gène mecA par PCR.

The presence of PBP2a can also be demonstrated by means of a latex agglutination test (Denka Senken, Oxoid) with a specificity of 100% and a sensitivity of > 97% 30 .
On peut également démontrer la présence de PBP2a à l’aide d’un test d'agglutination de particules au latex (Denka Senken, Oxoid) avec une spécificité de 100% et une sensibilité de > 97% 30 .

Other techniques that demonstrate mecA might become available in Belgium in the future (Evigene / Staten Serum Institute; Velogene rapid MRSA identification assay / ID Biomedical Corp).
D'autres techniques mettant en évidence le mecA pourraient devenir disponibles en Belgique dans le futur (Evigene / Staten Serum Institute; Velogene rapid MRSA identification assay / ID Biomedical Corp.).

Pfizer Inc.: Working together for a healthier world™ At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.